StockData
Cocrystal Pharma, Inc. logo

Cocrystal Pharma, Inc. (COCP) stock

COCPNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 16, 2026Score 5/30
$0.97−0.01 (-0.72%)

Close on Nov 19, 2026Market cap $18.68MP/E –Yield –

Cocrystal Pharma free cash flow

Free cash flow is cash from operations minus capital expenditures: the cash available for dividends, buybacks, debt repayment or acquisitions.

Cocrystal Pharma's free cash flow for the twelve months ending Dec 31, 2025 was -$8.20M. For fiscal 2025 it was -$8.20M. The highest annual figure on record is -$619.03K in fiscal 2010.

Annual free cash flow

PeriodPeriod endValueChange
FY2025Dec 31, 2025-$8.20M–
FY2024Dec 31, 2024-$16.49M–
FY2023Dec 31, 2023-$14.78M–
FY2022Dec 31, 2022-$21.51M–
FY2021Dec 31, 2021-$12.77M–
FY2020Dec 31, 2020-$10.07M–
FY2019Dec 31, 2019-$1.71M–
FY2018Dec 31, 2018-$8.32M–
FY2017Dec 31, 2017-$6.94M–
FY2016Dec 31, 2016-$14.71M–
FY2015Dec 31, 2015-$10.66M–
FY2014Dec 31, 2014-$6.02M–
FY2013Dec 31, 2013-$3.69M–
FY2012Dec 31, 2012-$1.74M–
FY2011Dec 31, 2011-$996.38K–
FY2010Dec 31, 2010-$619.03K–

Quarterly free cash flow

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q4 FY2025Dec 31, 2025-$1.74M–
Q4 FY2024Dec 31, 2024-$3.16M–
Q3 FY2024Sep 30, 2024-$5.12M–
Q2 FY2024Jun 30, 2024-$3.70M–
Q1 FY2024Mar 31, 2024-$4.51M–
Q4 FY2023Dec 31, 2023-$3.39M–
Q3 FY2023Sep 30, 2023-$2.68M–
Q2 FY2023Jun 30, 2023-$5.56M–
Q1 FY2023Mar 31, 2023-$3.16M–
Q4 FY2022Dec 31, 2022-$4.91M–
Q4 FY2021Dec 31, 2021-$2.93M–
Q3 FY2021Sep 30, 2021-$5.41M–
Q2 FY2021Jun 30, 2021-$2.64M–
Q1 FY2021Mar 31, 2021-$1.80M–
Q4 FY2020Dec 31, 2020-$2.38M–
Q3 FY2020Sep 30, 2020-$3.08M–
Q2 FY2020Jun 30, 2020-$2.33M–
Q1 FY2020Mar 31, 2020-$2.28M-214.5%
Q4 FY2019Dec 31, 2019-$1.23M–
Q3 FY2019Sep 30, 2019-$1.44M–
Q2 FY2019Jun 30, 2019-$1.03M–
Q1 FY2019Mar 31, 2019$1.99M–
Q4 FY2018Dec 31, 2018-$1.99M–
Q3 FY2018Sep 30, 2018-$2.16M–
Q2 FY2018Jun 30, 2018-$2.09M–
Q1 FY2018Mar 31, 2018-$2.08M–
Q4 FY2017Dec 31, 2017-$1.58M–
Q3 FY2017Sep 30, 2017-$2.19M–
Q2 FY2017Jun 30, 2017-$1.09M–
Q1 FY2017Mar 31, 2017-$2.09M–
Q4 FY2016Dec 31, 2016-$2.30M–
Q3 FY2016Sep 30, 2016-$3.16M–

More Cocrystal Pharma figures

See a number that looks wrong?